Sorbidilat SR 100 mg

Hauptinformation

  • Handelsname:
  • Sorbidilat SR 100 mg Retardkapseln
  • Darreichungsform:
  • Retardkapseln
  • Zusammensetzung:
  • isosorbidi dinitras 100 mg, color.: E 127, E 132, excipiens pro capsula.
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • allopathic Droge

Dokumenten

Lokalisierung

  • Erhältlich in:
  • Sorbidilat SR 100 mg Retardkapseln
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Synthetika human
  • Therapiebereich:
  • Koronartherapeutikum aus der Klasse der organischen Nitrate

Weitere Informationen

Status

  • Quelle:
  • Swissmedic - Swiss Agency for Therapeutic Products
  • Zulassungsnummer:
  • 36575
  • Berechtigungsdatum:
  • 01-09-1971
  • Letzte Änderung:
  • 12-09-2017

Packungsbeilage: zusammensetzung, kinische angaben, nebenwirkungen, wechselwirkungen, dosierung, schwangerschaft, stillzeit

Patienteninformation

Sorbidilat® SR Retardkapseln

Actavis Switzerland AG

Was ist Sorbidilat SR und wann wird es angewendet?

Sorbidilat SR enthält als Wirkstoff Isosorbiddinitrat. Es dient zur Vorbeugung von Angina-pectoris-

Anfällen (schmerzhafte Brustenge) und zur Behandlung der Herzschwäche bei oder nach einem

Herzinfarkt.

Sorbidilat SR darf nur auf Verschreibung und unter ständiger Kontrolle des Arztes bzw. der Ärztin

verwendet werden.

Wann darf Sorbidilat SR nicht angewendet werden?

Sorbidilat SR darf bei bekannter Überempfindlichkeit auf den Wirkstoff oder einen der Hilfsstoffe

sowie bei stark erniedrigtem Blutdruck nicht eingenommen werden.

Wichtiger Hinweis:

Wenn Sie als Patient mit einer Herzerkrankung (z.B. Angina pectoris) unter Behandlung mit

Sorbidilat stehen, dürfen Sie keinesfalls Sildenafil (Viagra®) und andere Arzneimittel der so

genannten Phosphodiesterase-Typ-5-Hemmer zur Behandlung der Impotenz des Mannes einnehmen.

Die gleichzeitige Anwendung von Viagra oder anderen Arzneimitteln dieser Gruppe kann eine

gefährliche Verstärkung der Wirkung von Sorbidilat in Form von Blutdruckabfall und

Kreislaufzusammenbruch verursachen.

Sollten Sie aber Viagra oder andere Arzneimittel dieser Gruppe (Phosphodiesterase-Typ-5-Hemmer)

dennoch eingenommen haben, ist die Anwendung von Sorbidilat innerhalb von 24 Stunden nach

Einnahme von Viagra oder anderen Arzneimitteln dieser Gruppe strikte verboten. Dies gilt auch im

Fall von plötzlich auftretenden Herzbeschwerden. Wenden Sie sich in dieser Notfallsituation an

einen Arzt und informieren Sie ihn über die Einnahme von Viagra oder anderen Arzneimitteln dieser

Gruppe.

Wann ist bei der Einnahme von Sorbidilat SR Vorsicht geboten?

Dieses Arzneimittel kann die Reaktionsfähigkeit, die Fahrtüchtigkeit und Fähigkeit, Werkzeuge oder

Maschinen zu bedienen, beeinträchtigen! Dies gilt in verstärktem Mass bei Behandlungsbeginn,

Dosiserhöhung sowie zusammen mit Alkohol.

Viele andere Arzneimittel, wie zum Beispiel andere blutdrucksenkende Mittel und

Dihydroergotamine, können die Wirkung von Sorbidilat SR beeinflussen. Eine Kombination mit

solchen Arzneimitteln ist zu vermeiden.

Informieren Sie Ihren Arzt oder Apotheker bzw. Ihre Ärztin oder Apothekerin, wenn Sie an anderen

Krankheiten leiden, Allergien haben oder andere Arzneimittel (auch selbstgekaufte) einnehmen oder

äusserlich anwenden!

Darf Sorbidilat SR während einer Schwangerschaft oder in der Stillzeit eingenommen werden?

Wenn Sie schwanger sind oder es werden möchten sowie in der Stillzeit darf Sorbidilat SR nur nach

Rücksprache mit dem Arzt oder der Ärztin eingenommen werden.

Wie verwenden Sie Sorbidilat SR?

Der Arzt oder die Ärztin wird aufgrund regelmässiger Untersuchungen die für Sie zutreffende

Dosierung festlegen.

Die Anfangsdosierung beträgt 1× täglich 1-3 Retardkapseln Sorbidilat SR 20 mg oder 1× täglich 1-2

Retardkapseln Sorbidilat SR 40 mg.

Als Standarddosierung empfiehlt sich 1× täglich 1 Retardkapsel Sorbidilat SR 100 mg. Falls

erforderlich, kann die Dosierung auf 1× täglich 2 Retardkapseln Sorbidilat SR 100 mg gesteigert

werden.

Sorbidilat SR Retardkapseln sollen am Morgen unzerkaut mit Wasser verabreicht werden.

Kinder und Jugendliche

Sicherheit und Wirksamkeit von Sorbidilat SR wurden bei Patienten unter 18 Jahren nicht

untersucht. Sorbidilat SR ist deshalb für die Anwendung bei Kindern und Jugendlichen nicht

empfohlen.

Ändern Sie nicht von sich aus die verschriebene Dosierung. Wenn Sie glauben, das Arzneimittel

wirke zu schwach oder zu stark, so sprechen Sie mit Ihrem Arzt oder Apotheker bzw. Ihrer Ärztin

oder Apothekerin.

Welche Nebenwirkungen kann Sorbidilat SR haben?

Folgende Nebenwirkungen können bei der Einnahme von Sorbidilat SR auftreten:

Sehr häufig können bei Behandlungsbeginn Kopfschmerzen auftreten, die erfahrungsgemäss

meistens nach einigen Tagen bei weiterer Einnahme abklingen. Durch individuelle Anpassung der

Dosierung kann diese Begleiterscheinung vermindert oder sogar vermieden werden.

Häufig kann ein Blutdruckabfall mit erhöhtem Puls, Benommenheit sowie einem Schwindel- und

Schwächegefühl auftreten.

Gelegentlich können Kollapszustände, Erbrechen, Übelkeit, Hautrötungen und allergische

Hautreaktionen vorkommen.

Wenn Sie Nebenwirkungen bemerken, die hier nicht beschrieben sind, sollten Sie Ihren Arzt oder

Apotheker bzw. Ihre Ärztin oder Apothekerin informieren.

Was ist ferner zu beachten?

Während einer Therapie mit Sorbidilat SR sollten keine alkoholischen Getränke eingenommen

werden, weil Alkohol die Wirkung des Arzneimittels in unvorhersehbarer Weise beeinflusst.

Sorbidilat SR soll bei Raumtemperatur (15–25 °C) und für Kinder unerreichbar aufbewahrt werden.

Das Arzneimittel darf nur bis zu dem auf dem Behälter mit «EXP:» bezeichneten Datum verwendet

werden. Falls Sie im Besitz von verfallenen Arzneimitteln sind, bringen Sie diese zur Entsorgung in

die Apotheke zurück.

Weitere Auskünfte erteilt Ihnen Ihr Arzt oder Apotheker bzw. Ihre Ärztin oder Apothekerin. Diese

Personen verfügen über die ausführliche Fachinformation.

Was ist in Sorbidilat SR enthalten?

1 Retardkapsel Sorbidilat SR 20 mg bzw. 40 mg enthält 20 mg bzw. 40 mg Isosorbiddinitrat sowie

Hilfsstoffe, u.a. den Farbstoff E 127 (Erythrosin).

1 Retardkapsel Sorbidilat SR 100 mg enthält 100 mg Isosorbiddinitrat sowie Hilfsstoffe, u.a. die

Farbstoffe E 127 (Erythrosin) und E 132 (Indigotin).

Zulassungsnummer

36575 (Swissmedic).

Wo erhalten Sie Sorbidilat SR? Welche Packungen sind erhältlich?

Sorbidilat SR erhalten Sie in Apotheken nur gegen ärztliche Verschreibung.

Von Sorbidilat SR 20 mg und 40 mg gibt es Packungen zu 20 und 100 Retardkapseln und von

Sorbidilat SR 100 mg zu 20 und 60 Retardkapseln.

Zulassungsinhaberin

Actavis Switzerland AG, 8105 Regensdorf.

Diese Packungsbeilage wurde im Juni 2014 letztmals durch die Arzneimittelbehörde (Swissmedic)

geprüft.

21-3-2019

Modification of the existing maximum residue levels for pyridaben in tomatoes and aubergines

Modification of the existing maximum residue levels for pyridaben in tomatoes and aubergines

Published on: Wed, 20 Mar 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Nissan Chemical Europe S.A.S. submitted a request to the competent national authority in the Netherlands to modify the existing maximum residue levels (MRLs) for the active substance pyridaben in tomatoes and aubergines. An MRL proposal of 0.15 mg/kg was derived for tomatoes and aubergines which reflects the intended use of the plant protection product containing pyridaben. Adequate analytical metho...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-3-2019

Modification of the existing maximum residue level for cyprodinil in Florence fennel

Modification of the existing maximum residue level for cyprodinil in Florence fennel

Published on: Wed, 20 Mar 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the FPS Health, Food chain safety and Environment of Belgium, submitted an application to modify the existing maximum residue level (MRL) for the active substance cyprodinil in Florence fennel to accommodate the intended use in the northern Europe. The submitted data were found sufficient to derive an MRL proposal of 4 mg/kg for cyprodinil in Florence fennel. Adequate analytical methods for enforcement are availa...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-3-2019

Safety and efficacy of eight compounds belonging to different chemical groups when used as flavourings for cats and dogs

Safety and efficacy of eight compounds belonging to different chemical groups when used as flavourings for cats and dogs

Published on: Tue, 19 Mar 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of 23 compounds belonging to different chemical groups. This opinion concerns eight out of the 23 compounds, which are currently authorised for use as flavours in food. The Panel concludes that the eight additives are safe for cats and dogs at the proposed use level: phenyl...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-3-2019

Safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters) when used as flavourings for all animal species and categories

Safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters) when used as flavourings for all animal species and categories

Published on: Tue, 19 Mar 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters). They are all currently authorised as flavours in food. The FEEDAP Panel was unable to perform the assessment of non‐2(c...

Europe - EFSA - European Food Safety Authority EFSA Journal

18-3-2019

Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter

Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter

Mylan Institutional LLC is conducting a voluntary nationwide recall of two lots (see table below) of Levoleucovorin Injection, 250 mg/25 mL to the consumer/user level. The lots were manufactured by Alidac Pharmaceuticals Limited and distributed by Mylan Institutional LLC.

FDA - U.S. Food and Drug Administration

16-3-2019

Efficacy of sodium formate as a technological feed additive (hygiene condition enhancer) for all animal species

Efficacy of sodium formate as a technological feed additive (hygiene condition enhancer) for all animal species

Published on: Fri, 15 Mar 2019 In 2015, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) issued an opinion on the safety and efficacy of formic acid, ammonium formate and sodium formate as feed hygiene agents for all animal species. In this opinion, two forms of the additive sodium formate, a solid form (specified to contain ≥ 98% sodium formate (w/w)) and a liquid form (specified to contain a minimum of 15% sodium formate, a maximum of 75% free formic acid and a maxim...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-3-2019

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient

Legacy Pharmaceutical Packaging, LLC is recalling 3 repackaged lots of Losartan Tablets USP 50mg to the consumer level. This recall was prompted due to Torrent Pharmaceuticals LTD issuing a Voluntary Nationwide Recall of Losartan Tablets, USP, due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, (API manufacturer).

FDA - U.S. Food and Drug Administration

16-3-2019

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmace

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmace

Earth City, MO, Legacy Pharmaceutical Packaging, LLC is recalling 40 repackaged lots of Losartan Tablets USP 25mg, 50mg, and 100mg to the consumer level. This recall was prompted due to Camber Pharmaceuticals, Inc. issuing a Voluntary Nationwide Recall of Losartan Tablets, USP, due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, (API manufacturer).

FDA - U.S. Food and Drug Administration

15-3-2019

Modification of the existing maximum residue level for fluopyram in broccoli

Modification of the existing maximum residue level for fluopyram in broccoli

Published on: Thu, 14 Mar 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Bayer Hellas AG submitted a request to the competent national authority in Greece to modify the existing maximum residue level (MRL) for the active substance fluopyram in broccoli. The data submitted in support of the request were found to be sufficient to derive MRL proposals for broccoli. Adequate analytical methods for enforcement are available to control the residues of fluopyram on the commodit...

Europe - EFSA - European Food Safety Authority EFSA Journal

14-3-2019

Safety of annatto E and the exposure to the annatto colouring principles bixin and norbixin (E 160b) when used as a food additive

Safety of annatto E and the exposure to the annatto colouring principles bixin and norbixin (E 160b) when used as a food additive

Published on: Wed, 13 Mar 2019 The Scientific Panel on Food Additives and Flavouring (FAF) provides a scientific opinion on the safety evaluation of annatto E and an exposure assessment of the annatto colouring principles bixin and norbixin (E 160b) when used as a food additive, taking into account new proposed uses and use levels. In 2016, the EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) adopted a scientific opinion on the safety of annatto extracts (E 160b) as a food additive....

Europe - EFSA - European Food Safety Authority EFSA Journal

14-3-2019

Safety evaluation of the food enzyme β‐glucanase, xylanase and cellulase from Mycothermus thermophiloides (strain NZYM‐ST)

Safety evaluation of the food enzyme β‐glucanase, xylanase and cellulase from Mycothermus thermophiloides (strain NZYM‐ST)

Published on: Fri, 08 Mar 2019 The food enzyme has three declared activities (endo‐1,3(4)‐β‐glucanase EC 3.2.1.6, endo‐1,4‐β‐xylanase EC 3.2.1.8 and cellulase (endo‐1,4‐β‐d‐glucanase EC 3.2.1.4)) and is produced with a non‐genetically modified Mycothermus thermophiloides strain by Novozymes A/S. It is intended to be used in baking and brewing processes. For the two intended uses, based on the maximum use levels recommended and individual data from the EFSA Comprehensive European Food Database, dietary e...

Europe - EFSA - European Food Safety Authority EFSA Journal

13-3-2019

Safety evaluation of the food enzyme triacylglycerol lipase from Aspergillus niger (strain LFS)

Safety evaluation of the food enzyme triacylglycerol lipase from Aspergillus niger (strain LFS)

Published on: Tue, 12 Mar 2019 The food enzyme triacylglycerol lipase (triacylglycerol acylhydrolase, EC 3.1.1.3) is produced with a genetically modified Aspergillus niger strain LFS by DSM Food Specialties B.V.. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The triacylglycerol lipase food enzyme is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the fo...

Europe - EFSA - European Food Safety Authority EFSA Journal

13-3-2019

Safety evaluation of the food enzyme glucose oxidase from Aspergillus niger (strain ZGL)

Safety evaluation of the food enzyme glucose oxidase from Aspergillus niger (strain ZGL)

Published on: Tue, 12 Mar 2019 The food enzyme glucose oxidase (β‐d‐glucose:oxygen 1‐oxidoreductase; EC 1.1.3.4) is produced with a genetically modified Aspergillus niger strain ZGL by DSM Food Specialties B.V.. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The glucose oxidase is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the food enzyme‐total orga...

Europe - EFSA - European Food Safety Authority EFSA Journal

9-3-2019

Safety evaluation of the food enzyme 4‐α‐glucanotransferase from Aeribacillus pallidus (strain AE‐SAS)

Safety evaluation of the food enzyme 4‐α‐glucanotransferase from Aeribacillus pallidus (strain AE‐SAS)

Published on: Fri, 08 Mar 2019 The food enzyme 4‐α‐glucanotransferase (1,4‐α‐d‐glucan:1,4‐α‐d‐glucan 4‐α‐d‐glycosyltransferase, EC 2.4.1.25) is produced with a non‐genetically modified Aeribacillus pallidus (previously identified as Geobacillus pallidus) strain from Amano Enzyme Inc. The food enzyme is intended to be used in baking processes and in starch processing for the production of modified dextrins. For baking processes, based on the maximum use levels recommended and individual data from the EFS...

Europe - EFSA - European Food Safety Authority EFSA Journal

9-3-2019

Safety of ethyl lauroyl arginate (E 243) as a food additive in the light of the new information provided and the proposed extension of use

Safety of ethyl lauroyl arginate (E 243) as a food additive in the light of the new information provided and the proposed extension of use

Published on: Fri, 08 Mar 2019 The present scientific opinion deals with the evaluation of the safety of the food additive ethyl lauroyl arginate (E 243) in the light of a new interpretation of the available toxicological data and with respect to the proposed changes to the currently authorised conditions of use. Ethyl lauroyl arginate (E 243) is an already authorised food additive in the EU for use in heat‐treated meat products only, with some exceptions. The safety of ethyl lauroyl arginate (E 243) as...

Europe - EFSA - European Food Safety Authority EFSA Journal

8-3-2019


Draft Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance

Draft Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance

Draft Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

8-3-2019

Safety assessment of the process ‘Jász‐Plasztik’, based on Vacurema Prime technology, used to recycle post‐consumer PET into food contact materials

Safety assessment of the process ‘Jász‐Plasztik’, based on Vacurema Prime technology, used to recycle post‐consumer PET into food contact materials

Published on: Thu, 07 Mar 2019 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of the recycling process Jász‐Plasztik (EU register number RECYC0157). The input are hot caustic washed and dried poly(ethylene terephthalate) (PET) flakes originating from collected post‐consumer PET containers and containing no more than 5% PET from non‐food applications. They are heated in a batch reactor under vacuum and then heated in a continuous reactor under vacuum...

Europe - EFSA - European Food Safety Authority EFSA Journal

7-3-2019

Norbrook Laboratories Limited Recalls Veterinary Products for Health Risk

Norbrook Laboratories Limited Recalls Veterinary Products for Health Risk

Norbrook Laboratories Limited of Newry, Northern Ireland is recalling two lots of Enroflox® 100 Injection (enrofloxacin), two lots of Noromectin® Injection (ivermectin) and two lots of Ivermax® 1% Injection (ivermectin) to the veterinarian/consumer level as a precautionary measure as product sterility cannot be assured. There is a concern that if the sterility of these products has been compromised, use of these products could result in introduction of infectious agents to the animal. This may result in ...

FDA - U.S. Food and Drug Administration

7-3-2019

American Health Packaging Issues Voluntary Nationwide Recall of Valsartan Tablets Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity

American Health Packaging Issues Voluntary Nationwide Recall of Valsartan Tablets Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity

American Health Packaging is voluntarily recalling one lot of Valsartan Tablets, USP, 160 mg to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the finished drug product is N-Nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Resea...

FDA - U.S. Food and Drug Administration

7-3-2019

Re‐evaluation of Quillaia extract (E 999) as a food additive and safety of the proposed extension of use

Re‐evaluation of Quillaia extract (E 999) as a food additive and safety of the proposed extension of use

Published on: Wed, 06 Mar 2019 The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) provides a scientific opinion on Quillaia extract (E 999) when used as a food additive and the evaluation of the safety of its proposed extension of use as a food additive in flavourings. The Scientific Committee for Food (SCF) in 1978 established an acceptable daily intake (ADI) of 0–5 mg spray‐dried extract/kg body weight (bw) per day for E 999. The Joint FAO/WHO Expert Committee on Food Additives ...

Europe - EFSA - European Food Safety Authority EFSA Journal

7-3-2019

Safety and efficacy of Robenz® 66G (robenidine hydrochloride) for chickens for fattening and turkeys for fattening

Safety and efficacy of Robenz® 66G (robenidine hydrochloride) for chickens for fattening and turkeys for fattening

Published on: Tue, 05 Mar 2019 Following a request from European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Robenz® 66G (robenidine hydrochloride (HCl)) when used as a feed additive for chickens for fattening and turkeys for fattening. The coccidiostat Robenz®66G is considered safe for chickens for fattening at the highest proposed level of 36 mg robenidine HCl/kg complete feed with a ...

Europe - EFSA - European Food Safety Authority EFSA Journal

5-3-2019

Morphine Sulfate Injection BP 30 mg in 1 mL ampoule

Morphine Sulfate Injection BP 30 mg in 1 mL ampoule

Safety advisory – Section 19A product not for epidural or intrathecal use

Therapeutic Goods Administration - Australia

20-3-2019

Methizol® SD 5 mg/- 20 mg

Rote - Liste

20-3-2019

Diacomit 250 mg Hartkapseln

Rote - Liste

20-3-2019

Diacomit 250 mg Pulver

Rote - Liste

20-3-2019

Diacomit 500 mg Pulver

Rote - Liste

20-3-2019

Diacomit 500 mg Hartkapseln

Rote - Liste

20-3-2019

Dopamin Fresenius 250/500 mg/50 ml

Rote - Liste

20-3-2019

Dopamin Fresenius 50/200 mg/5 ml

Rote - Liste

19-3-2019

Nevirapin Mylan 200 mg Tabletten

Rote - Liste

19-3-2019

Tramal® Kapseln, 50 mg, Hartkapseln

Rote - Liste

15-3-2019

Lamisil 250 mg Tabletten

Rote - Liste

15-3-2019

Vesikur 5 mg/10 mg Filmtabletten

Rote - Liste

15-3-2019

Irinotecan Kabi 20 mg/ml

Rote - Liste

15-3-2019

lbuSinex 200 mg/30 mg Filmtabletten

Rote - Liste

11-3-2019

PK-Merz® Filmtabletten 150 mg

Rote - Liste

11-3-2019

PK-Merz® Filmtabletten 100 mg

Rote - Liste

8-3-2019

REMODULIN 1 mg/ml Infusionslösung

Rote - Liste

8-3-2019

REMODULIN 10 mg/ml Infusionslösung

Rote - Liste

8-3-2019

REMODULIN 5 mg/ml Infusionslösung

Rote - Liste

8-3-2019

REMODULIN 2,5 mg/ml Infusionslösung

Rote - Liste

7-3-2019

Natrilix® SR 1.5 mg

Rote - Liste

7-3-2019

Azamedac® 50 mg Filmtabletten

Rote - Liste

6-3-2019

Konakion® MM 10 mg

Rote - Liste

6-3-2019

Aponal® 100

Rote - Liste

6-3-2019

L-Thyroxin Henning® 50/75/100 plus

Rote - Liste

6-3-2019

Xenical® 120 mg Hartkapseln

Rote - Liste

6-3-2019

Rohypnol® 1 mg Filmtabletten

Rote - Liste

6-3-2019

Konakion® MM 2 mg

Rote - Liste

6-3-2019

agnus sanol® 4 mg Hartkapseln

Rote - Liste